Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NuPathe, a specialty pharmaceutical company engaged in the development and commercialization of branded therapeutics, has reported net loss of $6.18m, or $0.42 loss per diluted share for the fourth quarter ended 31 December 2010, compared to net loss of $3.26m, or $11.26 loss per diluted share for the comparable period in 2009.
Subscribe to our email newsletter
The company has posted loss from operations of $6.2m, compared to $3.26m for the comparable period in 2009.
For the full year ended 31 December 2010, the company has posted a net loss of $24.36m, or $4.39 per diluted share, compared to $15.59m, or $50.31 per diluted share, for the year ago period.
NuPathe has further reported its loss from operations as $21.19m, compared to $14.45m for the year ago period.
NuPathe CEO Jane Hollingsworth said NuPathe ended 2010 with strong momentum, including the filing of the New Drug Application (NDA) for Zelrix for the treatment of acute migraine.
"We expect this momentum to build throughout 2011, with multiple data presentations at important scientific meetings, a PDUFA date for Zelrix and the commencement of human clinical trials for NP201 for Parkinson’s disease," Hollingsworth said.